Characteristics of the patients with axial spondyloarthritis included in the study
| Clinical parameters | SpA patients (n=61) |
| Age, years (mean±SD) | 40±13.3 |
| Male, n (%) | 47 (77) |
| Smoking (current smokers), n (%) | 26 (43) |
| Disease duration, years (mean±SD) | 6.4±9.9 |
| Axial disease, n (%) | 59 (97) |
| Peripheral disease, n (%) | 9 (15) |
| Enthesitis, n (%) | 29 (47.5) |
| Recurrent increased CRP (linked to the disease); n (%) | 33 (54) |
| Uveitis, n (%) | 18 (29.5) |
| IBD, n (%) | 0 (0) |
| Psoriasis, n (%) | 8 (13) |
| Familial SpA or SpA related condition, n (%) | 28 (46) |
| Biologic variables | |
| HLA B27-positive, n (%) | 48 (79) |
| Radiologic variables, n (%) | |
| mNY-SI-positive | 38 (62) |
| MRI-SI-positive* | 52 (85) |
| Current treatments, n (%) | |
| NSAIDs | 55 (90) |
| Steroids | 1 (1,6) |
| DMARDs | 9 (15)† |
| Anti-TNF received during the study, n (%) | |
| Ada/Gol | 8 (13)/14 (23) |
| Eta | 39 (64) |
| Disease activity at M0, mean±SD | |
| ASDAS-CRP | 2.9±1 |
| CRP (mean±SD) | 11.7±18.2 |
| Disease activity at M3, mean±SD | |
| ASDAS-CRP | 1.5±1 |
| CRP (mean±SD) | 2.7±5.6 |
| Response to treatment, n (%) | |
| ASDAS (R/PR/NR) | 10 (16)/25 (41)/26 (43) |
*Four patients with unavailable MRI data.
†Methotrexate n=4; sulfasalazine n=5.
Ada, adalimumab; ASDAS, Ankylosing Spondylitis Disease Activity Score; CRP, C reactive protein; DMARDs, disease-modifying anti-rheumatic drugs; eta, etanercept; goli, golimumab; IBD, inflammatory bowel disease; mNY, modified New-York criteria; NR, non-response; NSAIDs, non-steroidal anti-inflammatory drugs; PR, partial response; R, response; SI, sacroilitis; SpA, spondyloarthritis.